GET DAILY SIGNALSOutset Medical (OM) Delivers 14% Revenue Growth With Margin Expansion in Q3
Key Takeaways
- Total revenue rose about 14% year over year to $33.6 million, with product revenue up 15% to $23.7 million.
- Recurring revenue (consumables plus service) increased 10% to $23.1 million, underscoring a stable, predictable base.
- Non-GAAP gross margin reached 40.8%, up roughly 100 basis points from the prior-year period.
- Non-GAAP net loss was $12.9 million, compared with $12.4 million in the same quarter last year.
- Management reiterated full-year 2026 revenue guidance of $125 million to $130 million.
- The company ended the quarter with $140.7 million in cash, equivalents, short-term investments, and restricted cash.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Explore Trending AI Robots to see AI-driven trading strategies currently capturing market attention.
Why This Quarter Matters for Outset Medical
Outset Medical's quarterly update serves as an important checkpoint for investors following the company's progress toward profitability. The maker of the Tablo Hemodialysis System has focused in recent years on expanding gross margins, reducing cash burn, and narrowing losses, even as revenue has fluctuated with the timing of larger capital equipment orders. This report is notable because it indicates whether revenue growth is picking up again while margins continue to improve—a pairing that management has described as key to reaching the next target of 50% company-wide gross margin. In an environment where more hospitals are bringing dialysis services in-house, the results provide insight into demand for Tablo consoles and the associated recurring consumables.
Breakdown of the Reported Figures
For the third quarter ended September 30, 2026, OM posted total revenue of $33.6 million, an increase of approximately 14% from the year-ago period. Product revenue rose 15% to $23.7 million, supported by console revenue of $10.5 million (up 26%) and consumable revenue of $13.2 million (up 8%). Service and other revenue grew 12% to $9.9 million, and recurring revenue advanced 10% to $23.1 million. I also checked this using Tickeron’s AI Screener to compare the stock’s performance metrics against peers in the medical device space.
Non-GAAP gross margin came in at 40.8%, roughly 100 basis points higher than the prior-year quarter, reflecting product cost reductions, lower overhead, and service efficiencies. Product gross margin stood at 44.2%, while service and other gross margin improved 760 basis points to 32.4%. Non-GAAP operating expenses totaled $24.2 million, and the non-GAAP net loss was $12.9 million versus $12.4 million a year earlier. On a GAAP basis, the net loss narrowed to about $14.7 million from $17.8 million. The company reaffirmed its full-year 2026 revenue guidance of $125 million to $130 million and non-GAAP gross margin in the low-40% to mid-40% range.
How the Market Is Reading the Results
Investor expectations ahead of the release centered on a company still moving toward consistent profitability following a notable drop in its share price over the past year. The third-quarter numbers showed revenue growth returning to around 14% alongside a non-GAAP gross margin above 40%, which supports the margin-expansion story management has highlighted. The reaffirmed full-year outlook added a measure of stability to the forward view. Given that OM remains a growth-stage medical technology business with variability tied to capital equipment timing, the market’s response will likely focus on whether better margins and controlled spending can point to a clearer route to profitability.
Key Areas to Watch Going Forward
Investors will be monitoring several elements connected to Outset Medical’s console growth plan. Management has highlighted three main priorities: a refresh cycle covering more than 3,000 consoles with an estimated $150 million revenue opportunity over the next several years, deeper penetration at existing customer sites, and winning new accounts at hospitals that have not yet adopted the technology.
Margin improvement stays central. The company continues to aim for 50% company-wide gross margin, and the balance between lower-margin console sales and higher-margin consumables and service revenue will determine how quickly that target is reached. A heavier weighting toward consoles could keep gross margin toward the lower end of the guided range. Cash usage is also worth tracking. The company consumed $10.3 million in cash during the quarter and projects roughly $40 million for the full year, aided by expense discipline and working-capital management. With $140.7 million in cash and equivalents at quarter-end, the balance sheet remains a key focus as the firm works toward cash-flow breakeven. Broader trends in insourced dialysis, hospital capital budgets, and conversion rates in the commercial pipeline will further influence results into 2027.
Integrating AI Tools Into My Research Process
When analyzing names like OM, I often turn to Tickeron’s AI-powered platforms to cross-check technical patterns and fundamental trends against broader sector data. These tools help surface comparable ideas and validate signals without replacing my own review of the financials and guidance. In this case, they reinforced the view that margin expansion remains the primary driver to monitor alongside revenue reacceleration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OM's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for OM moved out of overbought territory on October 08, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 27 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 57 cases where OM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OM as a result. In 76 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for OM turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 34 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
OM broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
OM moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OM crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where OM advanced for three days, in 221 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 136 of 157 cases where OM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.866) is normal, around the industry mean (4.170). P/E Ratio (-1.168) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.483) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. OM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is Ethereum?
Which are the Four Most Common Indicators for Trend Trading?
Microsoft (MSFT) Stock Analysis: AI Leadership, Market Movements, and Financial Outlook May 28, 2025
The Art of Stock Trading: Price Action and Market Correlations
Understanding the Key Differences: Gold ETFs vs. Gold Futures?
General Information
Industry MedicalNursingServices
Advertisement